"Tight Control’ Of Inflammatory Biomarkers Improves Outcomes In Crohn’s Disease" - Adam Leitenberger
A treat-to-target strategy using “tight control” of inflammatory biomarkers in addition to clinical symptom monitoring led to improved outcomes in patients with Crohn’s disease on Humira, according to data from the CALM study. Detailed results were also recently published in The Lancet. “With this study, we have implemented a new concept of ‘tight control’ of Crohn’s disease, which will change the way that patients will be followed in clinical practice,” said Jean-Frédéric Colombel, MD, professor of medicine and gastroenterology at the Icahn School of Medicine at Mount Sinai and director of the Susan and Leonard Feinstein IBD Clinical Center at Mount Sinai. “Treatment should be based on objective markers of inflammation and not only on symptoms. A patient with Crohn’s disease may do well clinically, but if biomarkers for the disease remain high, we still need to escalate interventions including drugs. This study shows tight control led to more patients experiencing clinical remission, which will ultimately improve their long-term outcomes.”
- Jean-Frédéric Colombel, MD, Professor, Medicine, Gastroenterology, Icahn School of Medicine at Mount Sinai, Director, Susan and Leonard Feinstein IBD Clinical Center at Mount Sinai